LYMPHOMA, MYELOMA AND GENOMICS
Professor Dipti Talaulikar
Senior Consultant in Clinical and Laboratory Haematologist,
Canberra Health Services, Australia &
ANU School of Medicine and Psychology, The Australian National University
Canberra, Australia
RESEARCHER PROFILE
Filmed in Canberra, Australia | November 2025
Professor Dipti Talaulikar is a clinical and laboratory haematologist with expertise in genomics, working at Canberra Health Services, and Professor at ANU. She has a clinical and research interest in lymphoma, myeloma and genomics, and has authored close to 100 peer reviewed papers, including several clinical guidelines that have had a significant impact on clinical practice.
Professor Talaulikar is an inclusive and innovative educator, having been involved with teaching medical students since the inception of the ANU Medical School, and has won 5 awards including the Vice Chancellor awards for teaching and education.
Her conviction, that knowledge has to be linked with community work, has led her to develop The Link program at ANU, with a focus on sharing knowledge across boundaries. She is passionate about gender equity and has developed the Link and Grow Mentoring Program for diverse women in health and medicine.
She is the President branch of ASMOF (Australian Salaried Medical Officers Federation) and the chair of the Gender Equity Group in Federal ASMOF.
Source: Supplied
https://orcid.org/0000-0001-6766-8345
-
Oral administration of insulin for Type 1 Diabetes
Huiwen Pang is a 3rd year PhD candidate in the Australian Institute for Bioengineering and Nanotechnology, University of Queensland, focusing on biomedical health research. Prior to commencing his PhD, Huiwen studied animal genetics in his Masters degree at Huazhong Agriculture University in China.
People with diabetes, especially Type 1 diabetes, largely rely on the insulin injections or insulin pumps to control their high blood glucose levels, which is painful and has a high risk of infections.
Huiwen Pang is conducting research on nano-based drug formulations for Type 1 diabetes treatment, with a focus on using nanomaterials to load insulin for oral administration and employing anti-apoptotic and anti-inflammatory approaches to mitigate damage to beta cells.
-
Next generation nanomedicine and radiopharmaceuticals to treat cancer
Finding better ways of treating cancer, aside from finding a cure, aim to provide a better quality of life for those who suffer from it.
Professor Thurecht’s work focuses on nanomedicine and spans across the Australian Institute for Bioengineering and Nanotechnology and the Centre for Advanced Imaging, at the University of Queensland in Australia.
-
Environmental exposure to function of lung epithelial stem cell biology
Dr Clare Weeden has recently commenced as a Laboratory Head at WEHI in 2025, supported by the CSL Centenary Fellowship.
Dr Weeden specialises in lung epithelial cell biology in the context of homeostasis, inflammation, and lung cancer, particularly in people who don’t smoke. Her work endeavours to understand how past environmental exposures shape the responses of lung cells and the molecular mechanisms underlying this cellular recall, with the aim to develop novel early detection strategies for lung disease.
